AngioDynamics Announces Market Launch of SpeedLyser™ Thrombolytic Catheter
AngioDynamics Announces Market Launch of SpeedLyser™ Thrombolytic Catheter
April 13, 2004 at 12:00 AM EDT
AngioDynamics Announces Market Launch of SpeedLyser™ Thrombolytic CatheterQueensbury, NY, April 13, 2004 – ANGIODYNAMICS, INC., a wholly owned subsidiary of E-Z-EM, Inc., (AMEX: EZM) announced today the worldwide market launch of the SpeedLyser™ Thrombolytic catheter—a catheter kit intended for the administration of thrombolytic agents into the peripheral vasculature.
Unlike catheters constructed with side holes, the SpeedLyser™ thrombolytic catheter has slits to help evenly distribute the thrombolytic drug to the blockage. This new product also features a coaxial system – an innovative dual catheter combination of a 3F inner catheter within a 5F outer catheter – that simplifies access and drug delivery across the entire blocked graft. It also allows a physician to treat a blockage immediately after dissolving the blood clot by providing access for balloon angioplasty through the 5F catheter – an advantage that helps to minimize overall treatment time and patient discomfort. The SpeedLyser™ catheter will be offered in lengths of 10, 15, and 20cm, giving the physician greater flexibility in treating blockages of varying sizes and locations.
Commenting on the announcement, Robert M. Rossell, Vice President of Marketing for AngioDynamics, said, "The SpeedLyser™ utilizes our patented slit technology for applications in thrombolytic therapy. The product was developed in conjunction with leading Interventional Radiologists and will offer physicians a simplified way to maintain access in dialysis patients."
For additional information on the SpeedLyser™ Thrombolytic catheter, please contact Al Concemi at 1-800-772-6446, ext. 385, Email aconcemi@angiodynamics.com or visit the AngioDynamics web site at www.angiodynamics.com.
About AngioDynamics
AngioDynamics, Inc. (www.angiodynamics.com) is a leading provider of innovative medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease. AngioDynamics designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat PVD and other non-coronary diseases.
About E-Z-EM
E-Z-EM is a leading manufacturer of contrast agents for gastrointestinal radiology. The Company has developed the only CT injector on the market that can help detect contrast extravasation, the EmpowerCT® with patented EDA™ technology; it also offers a complete product set for the virtual colonoscopy practitioner. This product line consists of virtual colonoscopy hardware, software, nutritional prep kits and bowel cleaners, tagging agents and a carbon dioxide colon insufflation system.
The statements made in this document contain certain forward‑looking statements that involve a number of risks and uncertainties. Words such as “expects”, “intends”, “anticipates”, “plans”, “believes”, “seeks”, “estimates,” or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, market acceptance of The Speedlysertm Thrombolytic Catheter, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations, competition, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Form 10-Q for the quarter ended February 28,2004, as well as its Annual Report on Form 10-K for the year ended May 31, 2003, may affect the actual results achieved by the Company.
Company Contacts:
AngioDynamics, Inc.
Lisa Donegan
(800) 772-6446 x370
www.angiodynamics.com
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz (kgolodetz@lhai.com)
(212) 838-3777
Bruce Voss (bvoss@lhai.com)
(310) 691-7100
Unlike catheters constructed with side holes, the SpeedLyser™ thrombolytic catheter has slits to help evenly distribute the thrombolytic drug to the blockage. This new product also features a coaxial system – an innovative dual catheter combination of a 3F inner catheter within a 5F outer catheter – that simplifies access and drug delivery across the entire blocked graft. It also allows a physician to treat a blockage immediately after dissolving the blood clot by providing access for balloon angioplasty through the 5F catheter – an advantage that helps to minimize overall treatment time and patient discomfort. The SpeedLyser™ catheter will be offered in lengths of 10, 15, and 20cm, giving the physician greater flexibility in treating blockages of varying sizes and locations.
Commenting on the announcement, Robert M. Rossell, Vice President of Marketing for AngioDynamics, said, "The SpeedLyser™ utilizes our patented slit technology for applications in thrombolytic therapy. The product was developed in conjunction with leading Interventional Radiologists and will offer physicians a simplified way to maintain access in dialysis patients."
For additional information on the SpeedLyser™ Thrombolytic catheter, please contact Al Concemi at 1-800-772-6446, ext. 385, Email aconcemi@angiodynamics.com or visit the AngioDynamics web site at www.angiodynamics.com.
About AngioDynamics
AngioDynamics, Inc. (www.angiodynamics.com) is a leading provider of innovative medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease. AngioDynamics designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat PVD and other non-coronary diseases.
About E-Z-EM
E-Z-EM is a leading manufacturer of contrast agents for gastrointestinal radiology. The Company has developed the only CT injector on the market that can help detect contrast extravasation, the EmpowerCT® with patented EDA™ technology; it also offers a complete product set for the virtual colonoscopy practitioner. This product line consists of virtual colonoscopy hardware, software, nutritional prep kits and bowel cleaners, tagging agents and a carbon dioxide colon insufflation system.
The statements made in this document contain certain forward‑looking statements that involve a number of risks and uncertainties. Words such as “expects”, “intends”, “anticipates”, “plans”, “believes”, “seeks”, “estimates,” or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, market acceptance of The Speedlysertm Thrombolytic Catheter, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations, competition, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Form 10-Q for the quarter ended February 28,2004, as well as its Annual Report on Form 10-K for the year ended May 31, 2003, may affect the actual results achieved by the Company.
Company Contacts:
AngioDynamics, Inc.
Lisa Donegan
(800) 772-6446 x370
www.angiodynamics.com
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz (kgolodetz@lhai.com)
(212) 838-3777
Bruce Voss (bvoss@lhai.com)
(310) 691-7100